Mass staff layoff upheaval at the US Food and Drug Administration has also affected the off-patent drug offices on 1 April, warned trade group the Association for Accessible Medicines.
“AAM is deeply concerned by reports that key officials within the FDA’s generic drug and biosimilar programs and officials responsible...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?